NORTH CHICAGO, IL. and SAN DIEGO, CA, August 19, 2025 – AbbVie (NYSE: ABBV) and Capstan Therapeutics, Inc. (“Capstan”), a clinical-stage biotechnology company advancing in vivo engineering of cells through RNA delivery using targeted lipid nanoparticles (tLNPs), today announced the completion of AbbVie’s acquisition of Capstan for up to $2.1 billion. The transaction includes Capstan’s lead candidate, CPTX2309, a potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy currently in Phase 1 development for B cell–mediated autoimmune diseases, as well as Capstan’s proprietary tLNP platform technology designed to deliver RNA payloads, such as mRNA, to engineer specific cell types in vivo.
Science Significance
Capstan’s CPTX2309 represents a paradigm shift in cellular therapies. Unlike conventional CAR-T therapies that require extraction, genetic modification, and reinfusion of patient T cells, CPTX2309 uses tLNP delivery to reprogram T cells directly inside the body. By encoding anti-CD19 CAR in CD8+ cytotoxic T cells, the therapy targets and depletes pathogenic B cells, aiming for rapid, durable, and drug-free remission. This approach eliminates the need for lymphodepleting chemotherapy and bypasses complex ex vivo cell manufacturing, positioning AbbVie at the forefront of in vivo genetic medicine.
Regulatory Significance
The acquisition closed following clearance under the Hart-Scott-Rodino Antitrust Improvements Act, underscoring the regulatory scrutiny around large biotech transactions. As CPTX2309 progresses through Phase 1 clinical trials, regulators will face new challenges in evaluating in vivo cell engineering technologies, which blur the boundaries between biologics, cell therapy, and gene therapy. This acquisition highlights the need for updated regulatory frameworks that can address novel modalities in cellular reprogramming, long-term safety monitoring, and quality oversight.
Business Significance
Advertisement
At $2.1 billion, this deal represents AbbVie’s most significant immunology acquisition since the loss of Humira’s patent exclusivity. The move strategically strengthens AbbVie’s immunology franchise, diversifying its portfolio alongside key assets like Rinvoq and Skyrizi. Capstan’s scalable, off-the-shelf CAR-T approach addresses one of the biggest barriers in cell therapy: high cost and manufacturing bottlenecks. By integrating this platform, AbbVie positions itself as a leader in next-generation autoimmune therapeutics, balancing near-term risk with the potential for long-term market disruption.
Patients’ Significance
For patients, in vivo CAR-T therapy could mark a turning point in autoimmune care. CPTX2309 has the potential to provide curative, drug-free remission by resetting the immune system, rather than suppressing symptoms with lifelong therapies. Patients would benefit from a less invasive treatment that avoids chemotherapy preconditioning and eliminates reliance on specialized cell-manufacturing facilities. If successful, this innovation could make CAR-T-like outcomes more accessible to broader patient populations, including those previously unable to tolerate conventional approaches.
Policy Significance
AbbVie’s acquisition of Capstan signals the policy and healthcare system implications of in vivo reprogramming technologies. As these therapies move from oncology into chronic autoimmune diseases, reimbursement models, regulatory standards, and long-term monitoring policies will need to adapt. This transition challenges traditional frameworks that separate biologics, cell therapies, and gene therapies—demanding a new category of immune reset therapies. Policymakers will also face critical decisions around cost, equitable access, and healthcare sustainability as curative but high-value therapies enter mainstream use.
Bottom line: AbbVie’s integration of Capstan’s in vivo CAR-T technology represents a watershed moment in immunology—bringing together cutting-edge science, new regulatory challenges, business strategy, patient hope, and evolving healthcare policy into one transformative deal.
Source: Capstan Therapeutics, Inc Press Release
